Melanoma Treatment Trials Halted by Pfizer
Pharmaceutical company Pfizer Inc (NYSE: PFE) has announced they’re discontinuing Phase III clinical trials on tremelimumab, an experimental treatment for melanoma.
The company terminated the trials because their research indicates the developmental drug is no more effective than existing chemotherapies already approved to treat the potentially deadly skin cancer.
A representative from Pfizer Global Research and Development called tremelimumab’s trial results disappointing, but said the corporation remains committed to investigating new treatment options for melanoma patients.
If you’re a patient or health professional in the US who’d like to learn more about other therapies already approved for melanoma, you can visit the National Cancer Institute’s Melanoma Home Page.
Source: PharmaTimes.com
Related Links: American Cancer Society; Wall Street Journal; GenoMEL
Related Podcast: Melanoma from the University of Maryland Greenebaum Cancer Center
Technorati Tags: cutaneous malignancy; oncology; New London, Connecticut
Print This
|
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URI
Leave a comment
Browse All Categories: Next article: Cream Treats Precancerous Vulva Lesions Linked to HPV
Previous article: Fun and Free: Serious Science for The iPod Generation
